Rabia Khan

Rabia Khan is the Founder and CEO of Serna Bio, an AI-driven drug discovery company developing small molecules that modulate RNA translation and splicing. Serna Bio combines synthetic biology, machine learning, and high-throughput screening to drug the transcriptome, building the world’s largest database of druggable RNA motifs.

Rabia earned her Ph.D. in Human Genetics from McGill and an MBA from Concordia. Prior to Serna, she held leadership roles at Meta, BenevolentAI, and Sensyne Health, where she led scientific strategy, built discovery and data science teams, and secured partnerships with Bayer, BMS, Roche, and Alexion.